PMID- 34097244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210721
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 7
DP  - 2021 Jul
TI  - The Real-World Observational Prospective Study of Health Outcomes with 
      Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and 
      Baseline Characteristics.
PG  - 1929-1946
LID - 10.1007/s13300-021-01076-0 [doi]
AB  - INTRODUCTION: The TROPHIES observational study enrolled patients with type 2 
      diabetes mellitus (T2DM) initiating their first injectable treatment with the 
      glucagon-like peptide 1 receptor agonists (GLP-1 RAs) dulaglutide or liraglutide. 
      This manuscript focuses on the study design, baseline characteristics of the 
      enrolled population, and factors associated with GLP-1 RA choice. METHODS: 
      TROPHIES is a prospective, observational, 24-month study conducted in France, 
      Germany, and Italy. Inclusion criteria include adult patients with T2DM, naive to 
      injectable antihyperglycemic treatments, initiating dulaglutide or liraglutide 
      per routine clinical practice. The primary outcome is the duration of treatment 
      on dulaglutide or liraglutide without a significant treatment change. RESULTS: 
      The analysis included 2181 patients (dulaglutide, 1130; liraglutide, 1051) 
      (cutoff date May 15, 2019). The population was 56% male with mean [standard 
      deviation (SD)] patient characteristics at baseline as follows: age, 59.2 (11.0) 
      years; body mass index (BMI), 33.9 (6.6) kg/m(2); T2DM duration, 8.5 (6.9) years; 
      and glycated hemoglobin (HbA1c), 8.2 (1.3)%. Between-cohort demographic and 
      clinical characteristics were balanced. The mean (SD) HbA1c and BMI values for 
      French, German, and Italian patients were, respectively, 8.6 (1.4)%, 8.2 (1.4)%, 
      8.0 (0.8)%; 33.3 (6.1) kg/m(2), 36.0 (7.2) kg/m(2), and 32.6 (5.9) kg/m(2). 
      CONCLUSION: This study analysis at baseline provides an opportunity to evaluate 
      between-country differences in baseline HbA1c, weight, macrovascular 
      complications, and factors driving GLP-1 RA selection for patients with T2DM in 
      daily practice.
FAU - Garcia-Perez, Luis-Emilio
AU  - Garcia-Perez LE
AD  - Lilly, S.A., Avenida de La Industria, 30, 28108, Alcobendas, Spain. 
      garcia_luis-emilio@lilly.com.
FAU - Boye, Kristina S
AU  - Boye KS
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Rosilio, Myriam
AU  - Rosilio M
AD  - Lilly France SAS, Neuilly Sur Seine, France.
FAU - Jung, Heike
AU  - Jung H
AD  - Lilly Deutschland GmbH, Bad Homburg, Germany.
FAU - Heitmann, Elke
AU  - Heitmann E
AD  - Lilly Deutschland GmbH, Bad Homburg, Germany.
FAU - Norrbacka, Kirsi
AU  - Norrbacka K
AD  - Eli Lilly Finland, Helsinki, Finland.
FAU - Federici, Marco Orsini
AU  - Federici MO
AD  - Eli Lilly and Company Italia SpA, Florence, Italy.
FAU - Gentilella, Raffaella
AU  - Gentilella R
AD  - Eli Lilly and Company Italia SpA, Florence, Italy.
FAU - Guerci, Bruno
AU  - Guerci B
AD  - Hopital Brabois Adultes, CHRU de Nancy and University of Lorraine, Nancy, France.
FAU - Giorgino, Francesco
AU  - Giorgino F
AD  - University of Bari Aldo Moro, Bari, Italy.
FAU - Aigner, Ulrich
AU  - Aigner U
AD  - Versdias GmbH, Sulzbach-Rosenberg, Germany.
FAU - Sapin, Helene
AU  - Sapin H
AD  - Lilly France SAS, Neuilly Sur Seine, France.
LA  - eng
GR  - The study was funded by Eli Lilly and Company/Eli Lilly and Company/
PT  - Journal Article
DEP - 20210607
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC8266969
OAB - Dulaglutide and liraglutide are medications that can help people with type 2 
      diabetes mellitus (T2DM) to control their blood sugar levels. These medications 
      may also reduce body weight and reduce the risk of major cardiovascular disease. 
      Given these treatment effects, it is essential to know how they are used in 
      everyday clinical practice. Therefore, a study is being performed in three 
      countries (France, Germany, and Italy) in people with T2DM who had a first-ever 
      injectable therapy for T2DM with dulaglutide or liraglutide. Here, we present the 
      study design, the patient characteristics at the start of treatment, and the 
      factors driving the choice of one or the other medication. We analyzed data from 
      2181 people with T2DM. On average, it was shown that they were middle-aged and 
      obese. On average, these people were diagnosed with T2DM 8.5 years before the 
      start of dulaglutide or liraglutide and had high blood sugar levels when these 
      medications were started. The patient characteristics were slightly different 
      between the three countries. Country-specific factors driving the choice of 
      either medication were also identified.
OABL- eng
OTO - NOTNLM
OT  - Dulaglutide
OT  - Glucagon-like peptide 1 receptor agonists
OT  - Injectable therapy
OT  - Liraglutide
OT  - Observational study design
OT  - Patient characteristics
OT  - Type 2 diabetes
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
PMCR- 2021/06/07
CRDT- 2021/06/07 12:34
PHST- 2021/03/15 00:00 [received]
PHST- 2021/05/08 00:00 [accepted]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
PHST- 2021/06/07 12:34 [entrez]
PHST- 2021/06/07 00:00 [pmc-release]
AID - 10.1007/s13300-021-01076-0 [pii]
AID - 1076 [pii]
AID - 10.1007/s13300-021-01076-0 [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Jul;12(7):1929-1946. doi: 10.1007/s13300-021-01076-0. Epub 
      2021 Jun 7.